

REVIEW

CME CREDIT **EDUCATIONAL OBJECTIVE:** Readers will consider fertility preservation measures for young female patients newly diagnosed with cancer

ILARIA SOAVE, MD

Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy

GIUSEPPE LO MONTE, MD

Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy

EMILIO GIUGLIANO, MD

Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy

ANGELA GRAZIANO, MD

Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy

ROBERTO MARCI, PhD

Professor, Unit of Reproductive Medicine and Gynaecological Endocrinology, Department of Gynaecology-Obstetrics, Department of Experimental Medicine, University of Ferrara, Ferrara, Italy

Preserving fertility in female cancer patients: A snapshot of the options

ABSTRACT

With the odds of surviving cancer improving, many young women facing chemotherapy or radiotherapy may first wish to take steps to ensure that they will still be able to bear children afterward. The options depend on the type of disease, the treatment required, the age of the patient, whether she has a long-term partner, and whether cancer treatment can be delayed. This paper is an overview of current and experimental strategies for preserving fertility in female cancer patients.

KEY POINTS

Chemotherapy and radiotherapy are toxic to the ovaries, although the damage can be attenuated in some cases.

The standard option for preserving fertility has been oocyte retrieval after controlled ovarian stimulation, followed by in vitro fertilization and subsequent cryopreservation of the resulting embryos.

Unfortunately, controlled ovarian stimulation takes time, may delay needed cancer therapy, and may worsen estrogen-dependent cancers. Alternatives are being explored.

Cryopreservation of unfertilized oocytes is an option for women who do not have a partner, although oocytes are more susceptible to damage during freezing than embryos are.

IN THE LAST FEW decades, the survival rates have improved in many of the malignancies that affect young adults. This progress has made fertility preservation and quality of life after cancer treatment important, most of all in survivors of childhood cancers.

Men who are about to undergo cancer treatment can bank their sperm, but as yet no analogous noninvasive option is available for women. The most studied methods are often invasive and require the woman to take large doses of hormones. They may also necessitate a delay in starting cancer treatment.

Which method of fertility preservation a woman should choose depends on several factors, including the type of disease, the treatment required, the age of the patient, whether she has a long-term partner, and whether treatment can be delayed.

Chemotherapy and radiotherapy have well-known deleterious effects on female reproductive function. Many studies have shown that acute loss of growing follicles within the ovary and resultant premature ovarian failure often follow chemotherapy. This ovarian damage has long-term consequences, such as shortened reproductive life span and hormone deficiency.¹

Fertility preservation requires a team effort. It should be managed by an oncology center that has built a close collaboration between oncologists, fertility specialists, psychologists, and primary care physicians to allow early discussion and to offer a full range of options to these patients.

The aim of this paper is to discuss the current options for preserving fertility in female cancer patients who have to undergo gonadotoxic cancer treatment.

■ FEMALE FERTILITY AND ASSESSMENT OF OVARIAN RESERVE

At birth, baby girls have about 1 million primordial ovarian follicles, which is the most they will ever have. By the time they reach menarche, this number has declined to 180,000, and at menopause only about 1,000 remain.²

Throughout a woman's reproductive life, the number of oocytes remaining—both primordial follicles and the relatively small number of maturing, growing follicles—is called her *ovarian reserve*. When cancer is diagnosed, we need to assess the patient's ovarian reserve to direct the discussion about the need for fertility preservation.

In search of markers of ovarian reserve

Fertility experts have been looking for clinical biomarkers that could give us an estimate of the number of nongrowing follicles and, consequently, of the ovarian reserve.

All methods used for the assessment of ovarian reserve actually provide an indirect determination of the remaining pool of oocytes. In clinical practice, a high blood level of follicle-stimulating hormone (FSH) on cycle day 3 (>15 mU/mL) or a low level of anti-Müllerian hormone (AMH) (<1 ng/mL) is generally associated with a low ovarian reserve.

The serum FSH level is the marker most commonly used, but it varies widely at different times in the menstrual cycle.

The FSH test is usually performed on day 3 of the menstrual cycle, when the estrogen level is expected to be low due to negative feedback. The FSH result needs to be combined with the estradiol level, especially in those patients with irregular menstruation or in cases of amenorrhea. A random FSH test is considered valid if the detected estrogen level is low. Women undergoing in vitro fertilization with a day 3 FSH lower than 15 mIU/mL are more likely to conceive than women with a higher FSH level.

AMH and antral follicles. Recently, two other variables have been introduced in clinical practice: the AMH concentration and the antral follicle count (the number of small antral follicles within the ovary) as assessed by transvaginal ultrasonography.

AMH is released by the granulosa cells of small, growing follicles. Because its level is much more stable over the menstrual cycle than the FSH level, it can be measured on any day of the cycle.³ In cancer survivors, AMH is particularly useful in demonstrating the degree of ovarian tissue damage induced by radiotherapy and chemotherapy and in evaluating the ovarian reserve.⁴

A reduced number of antral follicles causes a diminished AMH production, which becomes undetectable with menopause. The AMH level is strongly associated with the basal antral follicle count. Various threshold values (0.2–1.26 ng/mL) have been used to identify women with low ovarian reserve.

■ HOW CANCER TREATMENT DAMAGES THE OVARIES

Advances in surgery, radiotherapy, and chemotherapy have significantly improved the prognosis for young cancer patients. However, cancer treatments often result in ovarian dysfunction, and premature menopause and irreversible sterility are the most dramatic outcomes. The resulting low estrogen levels, in addition to their physiologic consequences, also worsen quality of life through psychological effects, which can as well influence the patient's compliance with treatment.

Chemotherapy:

Alkylating agents are the most gonadotoxic

The mechanism by which chemotherapy affects ovarian function is poorly understood. Histologically, chemotherapeutic drugs could lead to ovarian atrophy and stromal fibrosis, to depletion of the primordial follicle stockpile, and to reduced ovarian weight, resulting in ovarian dysfunction.⁵

The patient's age correlates with the probability of ovarian damage or, inversely, ovarian resistance to chemotherapy. Young women have more primordial oocytes, and after chemotherapy they face a sharp reduction of their ovarian reserve. Still, younger patients show a lower rate of ovarian toxicity than older women.⁶

The type and the cumulative dose of cytotoxic agents used are other important variables.⁷ There are six main classes of chemo-

Men about to undergo chemotherapy can bank their sperm; women have no such simple option

TABLE 1

Choosing a fertility preservation option

Option	Appropriate for prepubertal girls	Sperm required	Delays cancer treatment	Requires controlled ovarian stimulation	Invasive	Experimental
Embryo cryopreservation	No	Yes	Yes	Yes	No	No
Metaphase II oocyte cryopreservation	No	No	Yes	Yes	No	No
Immature oocyte retrieval and in vitro maturation	No	No	No	No	No	Yes
Ovarian tissue cryopreservation	Yes	No	No	No	Yes	Yes

therapeutic drugs: alkylating agents, platinum derivatives, antibiotics, antimetabolites, plant alkaloids, and taxanes. They all affect ovarian function, but alkylating agents are the most gonadotoxic.

Alkylating agents covalently bind an alkyl group to the DNA molecule and inhibit it from replicating. In the ovaries they directly injure primordial oocytes and deplete follicles.⁸ They also seriously damage the ovarian vasculature so that the follicles cannot grow.⁹ Their destructive effect on the primordial follicles is dose-dependent and varies with the age and developmental maturity of the patient at the time of the therapy, with older women more likely to be left infertile afterward.¹⁰

Cyclophosphamide is an alkylating agent often used to treat severe manifestations of autoimmune diseases such as systemic lupus erythematosus, Behçet disease, steroid-resistant glomerulonephritis, inflammatory bowel disease, pemphigus vulgaris, and others. Because it can lead to premature ovarian failure and infertility, women receiving cyclophosphamide for autoimmune conditions may also need treatment to preserve fertility.¹¹

Radiotherapy

Ovarian follicles are remarkably vulnerable to damage from ionizing radiation, which results in ovarian atrophy and reduced follicle stores.¹

The risk of radiotherapy-induced infertility is closely related to the patient's age and

developmental maturity at the time of therapy and to dose fractionation and the extent of the irradiation field. Every patient has a different sensitivity to radiation damage that is probably genetically predetermined, but age seems to be the most important variable. Wo and Viswanathan¹² used a mathematical model devised by Wallace et al¹³ to show that the older the patient, the lower the radiation dose necessary to impair ovarian function.

The irradiation field is another aspect to consider. Pelvic radiation can be necessary in rectal cancer, cervical cancer, and lymphoma. In these cases, surgically moving the ovaries to a region outside the radiation field could be an option to minimize radiotherapy-induced ovarian damage.¹⁴

Radiotherapy can also damage the uterus. Pelvic irradiation can reduce uterine volume, alter uterine elasticity through myometrial fibrosis, and modify vascularization and endometrial thickness.^{15,16} These alterations are closely correlated with the total radiation dose, the site of irradiation, and the patient's age at the time of the treatment, the prepubertal uterus being more susceptible to damage.^{15,17} Larsen et al¹⁵ found that girls who received uterine irradiation before puberty had lower uterine volumes in adulthood than girls who received chemotherapy alone or radiation to other parts of the body, and that the younger the patient at the time of radiotherapy, the smaller the uterus later. These effects

The older the patient, the greater the risk of ovarian damage from chemotherapy

could result in adverse pregnancy outcomes.

Furthermore, radiation could also damage the uterine vasculature. Holm et al¹⁶ used ultrasonography to evaluate the effect of total-body irradiation and found that uterine volume and uterine blood flow were both impaired.¹⁵

All these possible alterations could lead to a reduced uterine response to cytotrophoblast invasion and to decreased fetoplacental blood flow, which could impair embryonic and fetal growth. In that case, a surrogate pregnancy would be the only method to achieve parenthood using the couple's gametes.

■ OPTIONS FOR FERTILITY PRESERVATION

Assisted reproductive technology

Young women diagnosed with an oncologic disease may wish to use assisted reproductive technology (TABLE 1) to keep open the possibility of having children at a later date. One approach is to harvest oocytes, fertilize them in vitro, and deep-freeze (cryopreserve) the resulting embryos to be thawed and implanted later. Alternatively, oocytes can be frozen directly, although success rates are lower with this method. And another approach is to obtain and cryopreserve ovarian tissue. If none of these is possible, oocytes may be obtained from a donor.

Controlled ovarian stimulation

If oocytes are to be harvested, a number of them should be harvested at one time.

There is not an optimal number of oocytes that should be retrieved, but cryopreservation of a large number of oocytes allows us to perform multiple attempts at in vitro fertilization, improving the chances of pregnancy. The fertilization rate (defined as the total number of zygotes at the 2-pronucleus stage divided by the number of fertilized oocytes) with intracytoplasmic sperm injection is 70% to 80%. On average, for every 10 eggs, 7 to 8 eggs will normally be fertilized. The implantation rate (defined as the total number of pregnancies divided by the total number of embryo transferred) with intracytoplasmic sperm injection is 40% to 50%—ie, only half of the transferred embryos will successfully implant and result in a pregnancy.

So that more than one ripe egg can be obtained at a time, the patient must undergo a regimen of controlled ovarian stimulation to achieve multifollicular growth. Stimulation protocols are based on giving pituitary hormones, ie, analogues of gonadotropin-releasing hormone (GnRH) (both agonists and antagonists), followed by recombinant FSH or human menopausal gonadotropin to promote follicular development. A single dose of human chorionic gonadotropin (hCG) is given to induce ovulation when the lead follicles have reached 18 to 20 mm in size.¹⁸

Many oncologists consider controlled ovarian stimulation dangerous for cancer patients because it takes time and thus delays cancer treatment. Furthermore, the regimen boosts the levels of circulating estrogens, which could be harmful in patients with hormone-dependent tumors.¹⁹

Oocytes can also be retrieved during unstimulated cycles. This avoids increasing estrogen concentrations above the physiologic level, but no more than a single oocyte is collected per cycle. The patient could undergo multiple oocyte harvestings, one per cycle, but this would delay her cancer treatment even more—by months—which is not recommended.

Serious efforts to minimize estrogen production during controlled ovarian stimulation have been made, although further studies are needed. Research is under way to develop appropriate ovarian stimulation protocols based on drugs with antiestrogenic effects.

Tamoxifen, an antagonist of the estrogen receptor, is widely used in breast cancer treatment.²⁰ It can also be given during controlled ovarian stimulation because it promotes follicular growth and induces ovulation.²¹ Oktay et al²² found that the embryo yield was 2.5 times higher in women with breast cancer treated with tamoxifen than in a retrospective control group consisting of breast cancer patients attempting natural-cycle oocyte retrieval.

Letrozole, an aromatase inhibitor, is also commonly used in treating breast and ovarian cancer. Aromatase is an enzyme that catalyzes the conversion of androgenic precursors to estrogens, and it is found in many tissues, including granulosa cells. Several studies report

Unlike FSH, AMH can be measured on any day of the cycle

the use of letrozole, alone or in combination with low doses of recombinant FSH, in ovarian stimulation protocols in cancer patients, with positive clinical outcomes.²³

Tamoxifen or letrozole, combined with recombinant FSH, is an attractive option in a controlled ovarian stimulation protocol for cancer patients,²⁴ although further investigation is needed.

Cryopreservation methods

Two main protocols are currently used to freeze oocytes, embryos, and ovarian tissue: slow freezing and vitrification.

In the slow-freezing method, cryoprotectant agents are used to draw water out of the cells, raising intracellular viscosity without (or with minimal) intracellular ice crystal formation, while the sample is cooled slowly in a controlled manner. These cryoprotectant chemicals lower the freezing point of the solution, allowing greater cellular dehydration during the slow freezing. They also protect the plasmatic cell membrane by changing its physical state from liquid to partially dry. To avoid excessive deformation that could damage the cytoplasmic structures, cryoprotectant agents are added in successive stages.²⁵

Vitrification is a newer method that uses higher concentrations of cryoprotectants and flash freezing. The instant drop in temperature converts this highly concentrated solution from an aqueous state to a semisolid, amorphous state that does not contain ice crystals, which are the main cause of damage during the freezing process.²⁶ Since most cryoprotectant agents are extremely toxic, it is necessary to minimize the time that oocytes, embryos, and ovarian tissue are exposed to them.

Cryopreservation of embryos

According to the American Society of Clinical Oncology and the American Society of Reproductive Medicine, embryo freezing is the most established method for fertility preservation, with tangible and widely reported success.²⁷ In normal practice, oocytes are retrieved after a controlled ovarian stimulation and then fertilized in vitro. Then they are treated with cryoprotectant agents, frozen, and stored. Upon demand, embryos can be thawed and implanted.

The Society for Assisted Reproductive Technology reports that the current live birth rate per transfer using thawed embryos from nondonor oocytes in US women under age 35 is 38.7%; at age 35 to 37 it is 35.1%.²⁸ In women with cancer, storing as many embryos as possible could help improve embryo survival and the implantation rate. The optimal time to perform embryo cryopreservation is still being discussed,²⁹ but, as in women without cancer, it is commonly done 3 to 5 days after fertilization.

In the past few years, the use of vitrification has greatly increased, as the post-thawing survival rates and pregnancy rates are higher with this method than with slow freezing.³⁰

Despite its success, embryo cryopreservation has important drawbacks. First, the patient must be of reproductive age and have a partner or accept the use of donor sperm. Second, most patients undergo controlled ovarian stimulation before oocyte retrieval, causing a delay in starting cancer treatment, which is not acceptable in many cases. Moreover, the high serum estrogen levels caused by ovarian stimulation may be contraindicated in women with estrogen-sensitive malignancies.¹⁹

Oocyte cryopreservation

Cryopreservation of oocytes avoids the need for sperm and, thus, may be offered to more patients than embryo cryopreservation. In addition, it may circumvent ethical or legal considerations associated with embryo freezing, such as ownership of reproductive material.

However, oocytes are more difficult to cryopreserve than embryos. Indeed, ice crystals frequently form inside and outside the cells, damaging the cell membrane and the meiotic spindle. In routine practice, mature oocytes in metaphase II are used for cryopreservation. Metaphase II oocytes are large cells that contain a delicate meiotic spindle. Moreover, their cytoplasm contains a higher proportion of water than other cells, which could affect their viability after freezing and thawing due to ice crystal formation. In addition, cryopreservation could be responsible for hardening of the zona pellucida (through diffuse thickening of the cell membrane), adversely affecting fertilization rates.³¹

Significant improvements were achieved

Women on cyclophosphamide for autoimmune conditions may also need fertility preservation treatment

in fertilization of cryopreserved oocytes with intracytoplasmic sperm injection. Nevertheless, there are still concerns regarding oocyte cryopreservation. Further studies are needed to determine the risk of aneuploidy caused by damage to the meiotic spindle after oocyte cryopreservation. The potentially detrimental effects of high cryopreservant concentrations used in vitrification also need to be investigated.

In vitro maturation

A novel fertility preservation strategy involves collecting immature oocytes from primordial follicles in unstimulated cycles and then letting them mature in vitro.

To date, immature oocytes retrieved at the germinal vesicle stage can be cryopreserved with vitrification followed by in vitro maturation after thawing, but several studies have demonstrated that better results are obtained when vitrification follows the in vitro maturation process.³²

Compared with mature oocytes, immature oocytes are less susceptible to damage during cryopreservation and thus have a better chance of surviving freezing and thawing, thanks to some peculiar characteristics: they are small, have few organelles, lack a zona pellucida, have low metabolic activity, and are in a state of relative quiescence.³³ Controlled ovarian stimulation is not necessary, so this procedure preserves fertility without delaying the start of cancer treatment.

Patients are usually evaluated with transvaginal ultrasonography in the early follicular phase of the menstrual cycle (between day 2 and day 4) to count and measure the antral follicles. Immature oocytes are collected when the leading follicle has reached 10 to 12 mm in size and 36 hours after a subcutaneous injection of hCG.³⁴ The retrieved oocytes are then incubated for 24 to 48 hours in a special medium supplemented with FSH and luteinizing hormone (LH). Immature oocytes can also be collected in the luteal phase.

This option could be considered when cancer treatment cannot be delayed for conventional follicular-phase retrieval³⁵ or in case of a premature LH surge during ovarian stimulation.³⁶ It should be offered to patients facing infertility related to cancer treatment only

after appropriate counseling and as a part of a clinical study.

Ovarian tissue cryopreservation

Cryopreservation of ovarian tissue is an experimental but highly promising technique for preserving fertility. Like oocyte cryopreservation, it avoids the need for hormonal stimulation and the need to delay cancer treatment. It may also be the only possible option for prepubertal girls, as well as for women who cannot postpone their cancer treatment. Although it is still experimental, it has obtained progressively better results: after having ovarian tissue preserved, thawed, and subsequently reimplanted in the same position or in a different part of the body, some patients transiently resumed having menstrual cycles and endocrine activity and in a very few cases achieved pregnancy.³⁷

Ovarian tissue for cryopreservation is usually taken via laparoscopic surgery, unless the patient has to undergo open laparotomy for another indication. Laparoscopic surgery offers significant advantages, such as the possibility of performing it on short notice without delaying oncologic therapy. Considering that women at age 30 have about 35 primordial follicles per square millimeter of ovarian tissue, 5 cubic fragments 5 mm wide may be sufficient to obtain more than 4,000 primordial follicles.³⁸ In cases in which complete ovariectomy is necessary, it is possible to remove and cryopreserve fragments of normal ovarian tissue located at the margins of the surgical specimen. Ovarian tissue withdrawal can also be performed in pediatric patients and during other surgical procedures.

The most studied method of cryopreserving ovarian tissue is slow freezing, but the use of vitrification is increasing. This technique was initially carried out in order to preserve the largest number of primordial follicles, but in recent years the possibility of cryopreserving the whole ovary with or without its vascular pedicle has also been studied. Martinez-Madrid et al³⁹ described a protocol of cryopreserving the entire ovary with its stem and found it possible to reach a follicular survival rate of 75%, preserving vessels and stromal structure.³⁹

Currently, the most promising approach

Many oncologists consider controlled ovarian stimulation dangerous because it can delay treatment

seems to be the transplantation of the ovarian tissue back into the donor, ie, autotransplantation. This avoids the need for immunosuppression.

The location can be either orthotopic or heterotopic. In orthotopic transplantation the tissue is placed back in its original location. In theory, the patient could then become pregnant in the usual way if the rest of the reproductive system is not damaged.

In heterotopic transplantation the tissue is placed in a different location, usually easily accessible, like the forearm or the subcutaneous abdominal area. Heterotopic transplants have been shown to be able to restore ovarian function, but not to give pregnancies after oocyte collection.⁴⁰ Indeed, the pregnancies obtained after transplantation came from autografts of ovarian cortex in orthotopic sites like the fossa ovarica or the remnant ovary.

With autotransplantation, there is a high risk of transmission of metastatic cancer cells. Blood-bone cancers such as leukemia and lymphomas are likely to be associated with the highest risk of ovarian metastasis through transplantation of thawed cryopreserved ovarian tissue. Neuroblastoma and breast cancer are associated with a moderate risk of metastasis to the ovaries. Ovarian involvement is extremely rare in Wilms tumor, lymphomas (except for Burkitt lymphoma), osteosarcomas, Ewing sarcoma, and extragenital rhabdomyosarcoma. Squamous cell cervical cancer metastasizes to the ovaries in fewer than 0.2% of cases, even in the most advanced stages. Histologic evaluation of ovarian samples before transplantation has been proposed to prevent cancer transmission, although it is not possible to completely abolish this risk.^{41,42} This jeopardy could potentially be eliminated by in vitro maturation of immature oocytes collected from cryopreserved ovarian tissue.

Despite significant advances, to date there have been fewer than 20 babies born worldwide through this method.⁴³

Oocyte donation

Assisted reproduction techniques also include in vitro fertilization using a sperm sample from the partner and oocytes from a donor. The embryos obtained are then transferred, saving the woman from ovarian stimulation without

any delay in starting the cancer treatment. Although this method has a high success rate, it inevitably raises personal considerations.

■ OVARIAN TRANSPOSITION

When a woman of childbearing age needs radiation treatment for a pelvic malignancy, transposition of the ovaries above the pelvic brim outside the radiation field (oophoropexy) should be considered before starting therapy. It is indicated in patients diagnosed with malignancies that require pelvic radiation but not the removal of the ovaries. It can be performed during surgical treatment of the tumor or as a separate laparoscopic procedure. The radiation dose that the transposed ovaries receive is considerably less than that in ovaries left in place.

Laparoscopic ovarian transposition is highly effective. However, the risk involved in the surgical procedure should not be underestimated. The most important complications are vascular injury, infarction of the fallopian tube, and ovarian cyst formation.⁴⁴

■ PHARMACOLOGIC PROTECTION

Some drugs induce a state of ovarian quiescence similar to menopause. Can they be used during chemotherapy to protect the ovaries, allowing restoration of normal ovarian function and natural fertility after cancer treatment and preventing premature ovarian failure?

GnRH analogues slow the cellular activity of the gonads, in theory making them less sensitive to damage by cytotoxic agents. Initially, the release of gonadotropins is stimulated (flare-up effect), but after 10 to 15 days pituitary GnRH receptors are down-regulated by internalization of receptors. Since chemotherapy affects mainly actively dividing cells such as mature ovarian follicles, the use of the analogues is based on the assumption that by reducing FSH levels, follicles will remain quiescent, decreasing their sensitivity to the gonadotoxic effect of chemotherapy.

In a randomized study of 281 patients with early breast cancer, Del Mastro et al⁴⁵ reported a reduction in the occurrence of early menopause in those treated with a GnRH analogue during chemotherapy after 1 year of follow-up. How-

Women facing pelvic radiotherapy can consider transposition of the ovaries above the pelvic brim

ever, the debate regarding the effect of GnRH analogues on the fertility of cancer patients is still open and needs further investigation.

In recent years, research has focused on imatinib, a new, potentially protective drug,⁴⁶

but a lot of work still needs to be done. To date, the use of GnRH analogues is not recommended outside of clinical studies, and it should be offered only after careful counseling about other options to preserve fertility. ■

REFERENCES

1. Meirrow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. *Clin Obstet Gynecol* 2010; 53:727–739.
2. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. *PLoS One* 2010; 5:e8772.
3. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Müllerian hormone and antral follicle counts. *Hum Reprod* 2010; 25:221–227.
4. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. *Hum Reprod* 2009; 24:982–990.
5. Oktay K, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. *Cancer* 2007; 110:2222–2229.
6. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. *Fertil Steril* 2010; 94:638–644.
7. Lee SJ, Schover LR, Partridge AH, et al; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol* 2006; 24:2917–2931.
8. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. *Hum Reprod* 1993; 8:2080–2087.
9. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. *Endocrinology* 2002; 143:2797–2807.
10. Aubard Y, Piver P, Pech JC, Galinat S, Teissier MP. Ovarian tissue cryopreservation and gynecologic oncology: a review. *Eur J Obstet Gynecol Reprod Biol* 2001; 97:5–14.
11. Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. *Rheumatology (Oxford)* 2008; 47:1506–1509.
12. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. *Int J Radiat Oncol Biol Phys* 2009; 73:1304–1312.
13. Wallace WH, Thomson AB, Saran F, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. *Int J Radiat Oncol Biol Phys* 2005; 62:738–744.
14. Gareer W, Gad Z, Gareer H. Needle oophoropexy: a new simple technique for ovarian transposition prior to pelvic irradiation. *Surg Endosc* 2011; 25:2241–2246.
15. Larsen EC, Schmiegelow K, Rechnitzer C, Loft A, Müller J, Andersen AN. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. *Acta Obstet Gynecol Scand* 2004; 83:96–102.
16. Holm K, Nysom K, Brocks V, Hertz H, Jacobsen N, Müller J. Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. *Bone Marrow Transplant* 1999; 23:259–263.
17. Critchley HO, Wallace WH, Shalet SM, Mamtara H, Higginson J, Anderson DC. Abdominal irradiation in childhood; the potential for pregnancy. *Br J Obstet Gynaecol* 1992; 99:392–394.
18. Goldberg JM, Falcone T, Attaran M. In vitro fertilization update. *Cleve Clin J Med* 2007; 74:329–338.
19. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. *FASEB J* 2002; 16:592–594.
20. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. *Lancet* 1992; 339:71–85.
21. Klopfer A, Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. *Br Med J* 1971; 1:152–154.
22. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. *Hum Reprod* 2003; 18:90–95.
23. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. *J Clin Oncol* 2005; 23:4347–4353.
24. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. *J Clin Oncol* 2005; 23:3858–3859.
25. Gosden R. Cryopreservation: a cold look at technology for fertility preservation. *Fertil Steril* 2011; 96:264–268.
26. Chen SU, Chien CL, Wu MY, et al. Novel direct cover vitrification for cryopreservation of ovarian tissues increases follicle viability and pregnancy capability in mice. *Hum Reprod* 2006; 21:2794–2800.
27. Lee SJ, Schover LR, Partridge AH, et al; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol* 2006; 24:2917–2931.
28. Society for Assisted Reproductive Technology (SART). <http://www.sart.org>. Accessed January 3, 2013.
29. Granne I, Child T, Hartshorne G; British Fertility Society. Embryo cryopreservation: evidence for practice. *Hum Fertil (Camb)* 2008; 11:159–172.
30. Loutradi KE, Kolibianakis EM, Venetis CA, et al. Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis. *Fertil Steril* 2008; 90:186–193.
31. Ko CS, Ding DC, Chu TW, et al. Changes to the meiotic spindle and zona pellucida of mature mouse oocytes following different cryopreservation methods. *Anim Reprod Sci* 2008; 105:272–282.
32. Cao Y, Xing Q, Zhang ZG, et al. Cryopreservation of immature and in vitro-matured human oocytes by vitrification. *Reprod Biomed Online* 2009; 19:369–373.
33. Toth TL, Baka SG, Veeck LL, Jones HW Jr, Muasher S, Lanzendorf SE. Fertilization and in vitro development of cryopreserved human prophase I oocytes. *Fertil Steril* 1994; 61:891–894.
34. Chian RC, Gülekli B, Buckett WM, Tan SL. Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome. *N Engl J Med* 1999; 341:1624, 1626.
35. Maman E, Meirrow D, Brengauz M, Raanani H, Dor J, Hourvitz A. Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. *Fertil Steril* 2011; 95:64–67.
36. Oktay K, Demirtas E, Son WY, Lostritto K, Chian RC, Tan SL. In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: description of a novel approach to fertility preservation. *Fertil Steril* 2008; 89:228.e19–e22.
37. Donne J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. *Lancet* 2004; 364:1405–1410.
38. Martinez-Madrid B, Dolmans MM, Van Langendonck A, Defrère S, Donne J. Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device. *Fertil Steril* 2004; 82:1390–1394.

39. **Martinez-Madrid B, Camboni A, Dolmans MM, Nottola S, Van Langendonck A, Donnez J.** Apoptosis and ultrastructural assessment after cryopreservation of whole human ovaries with their vascular pedicle. *Fertil Steril* 2007; 87:1153–1165.
40. **Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z.** Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. *JAMA* 2001; 286:1490–1493.
41. **Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology.** Ovarian tissue and oocyte cryopreservation. *Fertil Steril* 2008; 90(suppl 5):S241–S246.
42. **Oktay K.** Ovarian tissue cryopreservation and transplantation: preliminary findings and implications for cancer patients. *Hum Reprod Update* 2001; 7:526–534.
43. **Donnez J, Silber S, Andersen CY, et al.** Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. *Ann Med* 2011; 43:437–450.
44. **Terenziani M, Piva L, Meazza C, Gandola L, Cefalo G, Merola M.** Oophorectomy: a relevant role in preservation of ovarian function after pelvic irradiation. *Fertil Steril* 2009; 91:935.e15–e16.
45. **Del Mastro L, Boni L, Michelotti A, et al.** Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA* 2011; 306:269–276.
46. **Gonfloni S, Di Tella L, Caldarola S, et al.** Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. *Nat Med* 2009; 15:1179–1185.

ADDRESS: Roberto Marci, PhD, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Giovecca Street 183, 44100 Ferrara, Italy; e-mail: roberto.marci@unife.it



CME CALENDAR

2013

MAY

6TH ANNUAL ADVANCED MANAGEMENT ISSUES IN HIV MEDICINE: FOCUS ON HEPATITIS C VIRUS
 May 30–31
 Cleveland Clinic
 Cleveland, OH
www.ccfcmec.org/1HIV13

18TH ANNUAL DIABETES DAY: COMPLICATIONS OF DIABETES
 May 31
 Cleveland Clinic
 Cleveland, OH
www.ccfcmec.org/diabetesday13

JUNE

DEMENTIA 2013
 June 1
 Keep Memory Alive Event Center
 Las Vegas, NV

25TH ANNUAL INTENSIVE REVIEW OF INTERNAL MEDICINE
 June 2–7
 Cleveland Clinic
 Cleveland, OH
www.ccfcmec.org/3IRIM13

MELLEN CENTER UPDATE ON MULTIPLE SCLEROSIS
 June 21
 Cleveland Clinic
 Cleveland, OH
www.ccfcmec.org/MS13

AUGUST

2013 NEUROLOGY UPDATE: A COMPREHENSIVE REVIEW FOR THE CLINICIAN, FEATURING SELF-ASSESSMENT EXAMINATION
 August 2–4
 Ritz-Carlton Hotel
 Washington, DC
www.ccfcmec.org/NeuroUpdate13

ENDOCRINOLOGY BOARD REVIEW
 August 16–18
 Cleveland Clinic
 Cleveland, OH

14TH ANNUAL INTENSIVE REVIEW OF CARDIOLOGY
 August 18–21
 Cleveland Clinic
 Cleveland, OH
www.ccfcmec.org/Cardioreview13

SEPTEMBER

KIDNEY STONES: MEDICAL, SURGICAL, AND DIETARY APPROACHES
 September 6
 Glickman Conference Center
 Cleveland Clinic
 Cleveland, OH
www.ccfcmec.org/stones13

INTENSIVE REVIEW OF GASTROENTEROLOGY AND HEPATOLOGY
 September 9–12
 Hilton San Diego on Mission Bay
 San Diego, CA
www.ccfcmec.org/GIreview13

GASTROINTESTINAL HEMORRHAGE UPDATE
 September 18–20
 Ritz-Carlton Hotel
 Cleveland, OH

LUNG SUMMIT: ADVANCES IN PULMONARY MEDICINE, CRITICAL CARE MEDICINE, AND MECHANICAL VENTILATION
 September 25–27
 Cleveland Clinic
 Cleveland, OH

OCTOBER

2013 PRIMARY CARE WOMEN'S HEALTH: ESSENTIALS AND BEYOND
 October 3–4
 Corporate College East
 Warrensville Heights, OH

NEPHROLOGY UPDATE 2013
 October 10–12
 Ritz-Carlton Hotel
 Cleveland, OH

FOR SCHEDULE UPDATES AND TO REGISTER ONLINE, VISIT WWW.CCFMCE.ORG